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In order to explore possible mechanisms involved in
the previously documented turnover of mast cell
subpopulations in human cutaneous scars, we have
examined selected factors known to stimulate and/or
modulate mast cell hyperplasia (SCF, NGF, TGFb1,
GM-CSF) and their receptors in human cutaneous
scar tissue. On immunohistochemistry, numbers of
SCF- and TGFb1-positive cells were signi®cantly
increased in the epidermis and throughout the
dermis in scars (n= 27) of varying ages (4±369 d old),
compared with normal skin (n= 12). Furthermore,
TRbRI, II, and the NGF-p75 receptors were signi®-
cantly increased in the epidermis, TRbRI and
NGF-TrkA throughout the dermis, and TRbRII,
NGF-p75, and GM-CSFR only in the mid- and
lower dermis of scars. NGF and GM-CSF expression
was in contrast scarce and weak, with no differences
between normal skin and scars. In tissue extracts,
mRNA levels of SCF, TGFb1, TRbI and II, and both
NGF-receptors, but not GM-CSFR, were signi®-
cantly increased as well. TRbI and II were identi®ed
in up to 90% and 83%, respectively, of isolated
normal skin mast cells on ¯ow cytometry, and
GM-CSFR and NGFR-p75 were identi®ed on 70%
and 73%, respectively, of avidin-positive normal
mast cells on double immuno¯uorescence micro-
scopy. As described before for the SCF receptor
KIT, GM-CSFR and NGFR-p75 were partly or
entirely downregulated on avidin-positive mast cells
in scars. The marked upregulation of TGFb1, its
type I and II receptors, and SCF suggest that these
factors play a major role in the orchestration of mast
cell increase in human cutaneous scars whereas the
role of NGF and GM-CSF is less clear, despite the
signi®cant upregulation of their receptors. Key words:
GM-CSF/NGF/SCF/TGFb/wound healing. J Invest
Dermatol 116:387±393, 2001
M
ast cells have been implicated in the past to
participate in various aspects of cutaneous
wound healing (reviewed in Artuc et al, 1999).
Furthermore, we have recently shown that
resident, chymase+, avidin+ mast cells are
markedly decreased in cutaneous scars whereas immature mast
cells with the phenotype KIT+, tryptase+, chymase±, avidin± are
markedly increased (Hermes et al, 2000). Until now, the
mechanisms and molecules potentially inducing these changes have
not been investigated. It is, however, well established that mast cells
arise from myeloid stem cells in the bone marrow and that speci®c
growth and chemotactic factors regulate their growth, chemotaxis,
and survival in the tissue (reviewed in Metcalfe et al, 1997; Welker
et al 2000a).
Stem cell factor (SCF) which induces its biologic effects via a
transmembrane tyrosine kinase type III receptor named KIT
expressed only on mast cells and melanocytes in the skin, is the best
studied of these factors. In humans, it increases mast cell
proliferaton, differentiation, survival, chemotaxis, and secretion
(Nilsson et al, 1994; Hartmann et al, 1997; review in Grabbe et al,
1994) as well as accumulaton in vivo (Costa et al, 1996).
Nerve growth factor (NGF) is comparable with SCF with regard
to its in vitro effects on human mast cell differentiation (Welker et al,
1998, 2000b), but it exerts no chemotactic or antiapoptotic
activities (Hartmann et al, 1997; Henz et al 2000). Its biologic
activities are mediated via a 75 kDa (p75) receptor glycoprotein
that is found primarily in nervous tissue, and a 140 kDa tyrosine
kinase (TrkA) NGF receptor that is found on keratinocytes,
melanocytes, various myeloid cells, and recently also on immature
human mast cells (review in Henz et al, 2000).
Members of the transforming growth factor (TGF) b family are
recognized to play an important role in tissue remodeling
(Lawrence, 1996; O'Kane and Ferguson, 1997). In both murine
and human mast cells, TGFb induces a far more powerful
chemotactic response than SCF (Gruber et al, 1994; Mattoli et al,
1995; Olsson et al, 2000). It also upregulates murine mast cell
mediator production (Miller et al, 1999), but is ineffective with
regard to the stimulaton of mast cell proliferation and survival
(Broide et al, 1989; Mekori and Metcalfe, 1994; Welker et al, 1998;
Olsson et al, 2000). Selective TRb expression has been reported so
far only on mast cell lines (Gruber et al, 1994; Olsson et al, 2000).
Granulocyte macrophage-colony stimulating factor (GM-CSF),
a multipotent hematopoietic growth factor, induces proliferation of
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early mast cell progenitors, but interferes with early steps of mast
cell differentiation (Du et al, 1997) as well as maturation (Welker
et al, 1997). It binds to a GM-CSF-speci®c low af®nity 45 kDa a-
subunit and a 120 kDa b-subunit, which together form a high
af®nity binding site that is expressed on most mature leukocytes,
dendritic, and endothelial cells (Gearing et al, 1989; Bussolino et al,
1989; KaÈmpgen et al, 1994).
All these four growth factors are also of special interest since
they can be produced by human mast cells themselves (Nilsson et al,
1994, 1997; MoÈller et al, 1998; Kanbe et al, 1999; Welker et al,
1999), so that they could regulate mast cell in¯ux and differentia-
tion in an autocrine fashion.
In this study, we have studied the four growth factors and their
receptors for their expression in human scars at the protein and
mRNA level, except for data on the SCF receptor KIT, which
were reported before (Hermes et al, 2000). The data demonstrate
for the ®rst time a potential role of mast cell growth factors in
human cutaneous scaring and underline the importance of TGFb1
during this process.
MATERIALS AND METHODS
Tissue The tissue studied here was the same as that reported on recently
(Hermes et al, 2000). Brie¯y, scar specimens (n = 20) were from reexcisions
of 5±369 d melanoma scars and were in part analysed separately for
differences in fresh (5±34 d, N = 7) versus old scars (35±369 d, N = 13).
Normal tissue from 10 normal subjects served as control. Biopsies from
scars of seven additional melanoma patients and biopsies from their normal
skin at a distance from the scars were studied for further analyses. Biopsy
specimens were snap frozen and stored at ±80° until analysis. Isolated skin
mast cells were obtained from plastic surgery, with consent of the patients.
Determination of growth factor and receptor proteins
Immunohistochemistry was done on cryostat sections ®xed in 10%
acetone, using the APAAP methodology, as described before
(Schadendorf et al, 1991). The following antibodies were studied: All
murine monoclonal antibodies against the a-chain of the GM-CSF
receptor (GM-CSFR; Cdw116) (IgG2a) (Genzyme, Cambridge, MA), and
against the NGFR-p75 (Boehringer, Mannheim, Germany), NGFR-
TrkA, SCF, NGF, GM-CSF, TGFb1, TGFbRI, TGFbRII (all IgG1)
(Santa Cruz Biotechnology, Santa Cruz, CA). Murine monoclonal
antibodies against human desmin (IgG1) (Dianova, Hamburg, Germany)
and an unspeci®c one of the IgG2a isotype (Immunotech, Marseille,
France) served as negative controls.
Double staining for avidin in combination with immuno¯uorescence
was done for identi®cation of mast cell receptors by adding ¯uorescein
(DTFA)-conjugated egg white avidin (Jackson Immuno Research
Laboratories, West Baltimore), together with the primary antibody during
the ®rst step of the immuno¯uorescence reaction. Subsequently, a
secondary ¯uorochrome-conjugated antibody (Cy3TM-conjugated
Af®niPure F(ab)2 fragment goat anti-mouse IgG, Dianova) was added,
using the methodology described (Bergstresser et al, 1984; Haas et al, 1995;
Hermes et al, 2000). Sections were evaluated as described before (Hermes
et al, 2000). Brie¯y, dermal cells were counted in different compartments at
4003 magni®cation in a microgrid covering 6.25 nm2 or as numbers/
6.25 nm epidermal length. Avidin-APAAP double stained sections were
counted and photographed at 10003 magni®cation, using a ¯uorescence
axioscope HB050 (Zeiss, Oberkochem, Germany) and ®lter set 09
(excitation 450±490 nm) for avidin staining and ®lter set 15 (excitation
546/12) for evaluation of the immunohistological reactions.
Mast cells were isolated from dermal tissue by a sequence of enzymatic
digestions, followed by magnetic cell sorting system (MACS, Miltenyi
Biotec, Bergisch Gladbach, Germany) using the monoclonal antibody anti-
CD117 (YB5.B8, kindly provided by Mrs. Ashman, Adelaide, Australia).
Mast cell purity determined by toluidin blue staining was 92%±95%. For
FACS analysis, cells were blocked with mouse IgG and 5 3 104 incubated
for 30 min at 4°C with antibodies in 100 ml PBS (w/o Ca2+, Mg2+, 2% fetal
calf serum), washed and analyzed by ¯ow cytometry, as recently described
(Lippert et al, 1998).
RT-PCR Biopsies were lyzed and total RNA prepared using the
RNeasy-total-RNA-kit (Quiagen, Hilden, Germany). cDNA was
synthesized by reverse transcription of 5 mg total RNA, using a cDNA
synthesis kit (InVitrogen, Groningen, Netherlands). The following sets of
oligonucleotide primers were used to amplify cDNA: GAPDH: 5¢GAT
GAC ATC AAG AAG GTG GTG and 5¢GCT GTA GCC AAA TTC
GTT GTC (197 bp) (Tokunaga et al, 1987); TGFbRI: 5¢ TAG CTG AAA
TTG ACC TAA TTC CTC G and 5¢ TGC GGT TAT GGC AGA TAT
AGA CC (310 bp) (Suzuki et al, 1994); TGFbRII: 5¢ AGA CTG ACT
TGC GAC AAC CAG and 5¢ GAC TGC TGG TGG TGT ATT CTT
CCG (250 bp) (Lawler et al, 1994); TGFb1: 5¢ CGG GGC GAC GAC
CTG GGC ACC ATG CAT GAC and 5¢ CTG CTC CAC CTT CCC
CTT GCG ACC CAC (187 bp) (Stratagene, Heidelberg, Germany);
NGF: 5¢ TCA TCA TCC CAT CCC ATC TTC CAC and 5¢ CAC AGC
CTT CCT GCT GAG CAC ACA (348 bp) (Tam et al, 1997); NGFR-
p75: 5¢TGA GTG CTG CAA AGC CTG CAA and 5¢TCT CAT CCT
GGT AGT AGC CGT (230 bp); NGFR-TrkA: 5¢GGC TCC TCG GGA
CTG CGA TG and 5¢CAG GAG AGA GAC TCC AGA GCG (260 bp)
(Herrmann et al, 1993); GM-CSFR: CTT CTC TCT GAC CAG CA and
5¢ ACA TGG GTT CCT GAG TC (530 bp) (Guillaume et al, 1993); GM-
CSF: 5¢ACA CTG CTG AGA TGA ATG AAA CAG TAG and 5¢ TGG
ACT GGC TCC CAG CAG TCA AAG GGG ATG (285 bp, Stratagene);
SCF: 5¢GGG CTG GAT CGC AGC GC and 5 ¢CTC CAC AAG GTC
ATC CAC (Longley et al, 1993). Ampli®cation was performed using taq
polymerase (GIBCO) over 24±40 cycles with an automated thermal cycler
(Perkin Elmer, Weiterstadt, Germany). Each cycle consisted of the
following steps: denaturation at 94°C, annealing at 56°C, and extension
at 72°C for 1 min each. For semiquantitative RT-PCR, cDNA from the
different tissues was adjusted to equal quantities by serial dilutions, with the
housekeeping gene GAPDH as control, as previously described (Grabbe
et al, 1996; Hermes et al, 2000). Linearity of the signal for GAPDH was
determined between 24 and 27 cycles, and for the other markers between
30 and 40 cycles. PCR products were analyzed by agarose gel
electrophoresis and enzymatic digestion using standard techniques and
visualized by ethidium bromide staining. Intensity of each signal was
quantitatively assessed by densitometric analysis with a video scanner and
the software ScanPack 3.0 (Biometra, GoÈttingen, Germany).
Statistics Statistical signi®cance was calculated using the unpaired two-
tailed Student t test, with the advice of the Medical Statistics and
Information Department of the Free University, Berlin, Germany.
RESULTS
Expression of mast cell growth modulating factors In
normal skin, SCF was prominently expressed in cells known to
produce the factor, namely throughout the epidermis in
keratinocytes and in the dermis in endothelial cells, and less
intensely expressed in ®broblasts and in perivascular cells at
locations where mast cells are known to reside (Fig 1a). This
staining pattern was noted also in scar tissue, but staining was more
intense and involved signi®cantly more cells in all cutaneous
compartments, particularly ®brous scar tissue (Figs 1b, 2). SCF
message was also signi®cantly increased in scar tissue (Fig 3,
Table I).
In accordance with its well-recognized prominent role in
scarring (Shah et al, 1995), TGFb1 was markedly upregulated in
epidermal and dermal scar tissue (Table II). As with SCF, staining
was prominent in keratinocytes, ®broblasts, endothelial, and
perivascular cells, with more intense and extensive staining in scar
tissue. Furthermore, mRNA expression was also signi®cantly
upregulated in scars (Fig 3, Table I).
In contrast to the ®ndings with SCF and TGFb1, staining for
NGF and GM-CSF was weak and only minor, affecting only rare
epidermal and dermal cells, with no differences between normal
and scar tissue, also at the mRNA level (not shown).
Receptor expression for mast cell growth modulating
factors We have previously reported that in scar tissue,
expression of the SCF-receptor KIT is increased in dermal mast
cells and downregulated in epidermal melanocytes (Hermes et al,
2000). For both TRb I and II, there was also an enhanced
expression of immunoreactivity in the dermis (Table III), but
throughout the epidermis as well, and the message for both
receptors was also signi®cantly increased in tissue extracts (Fig 3,
Table I). Signi®cant upregulation of TRbII was only found,
however, in the mid- and lower dermis of scar compared with
normal tissue (Table III), and the message in scars was not
upregulated as markedly as with TRbI (Fig 3, Table I).
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The distribution of NGFR-TrkA reactive cells was similar to
that of the TGFb receptors, but staining of sweat glands was
particularly prominent, and in epidermal keratinocytes the basal
layer was nonreactive, with staining being restricted instead to the
mid-epidermal layers (not shown). Upregulation in scar tissue was
statistically signi®cant only in the dermis, in the same distribution as
in normal skin (Table III). In contrast, NGFR-p75 reactivity in
normal skin specimens was restricted to a few basal epidermal cells,
especially above the dermal papillae, and in the dermis on vessel,
nerve, muscle, and outer root sheath cells (Fig 4a). In scar tissue,
epidermal NGFR-p75 reactivity was barely detectable, and in the
dermis, an increased reactivity on vascular and perivascular cells was
evident only in the mid-and lower dermis (Fig 4b; Table III).
mRNA levels for both NGF receptors were also upregulated in
scars, with much higher values for TrkA (Fig 3, Table I).
Compared with all other receptors, numbers of GM-CSFR-
reactive cells were scarce in normal epidermis and dermis (Fig 5a,
Table III). In scars, values increased signi®cantly only in the mid-
and lower dermis (Fig 5b, Table III). Overall values for the entire
Figure 2. SCF immunoreactivity in normal skin versus scar tissue.
Results are expressed as means 6 SD of positive cells per 6.25 nm width in
the epidermis (epid) and cells per 6.25nm2 in the upper (u), mid- (m), and
lower (l) dermis. p values were 0.0007, 0.001, 0.0007, and 0.002 for the
differences between normal skin (ns) and scars in the four cutaneous
compartments, respectively.
Figure 3. Expression of mRNA for different growth factors and
growth factor receptors compared with GAPDH in scar tissue and
normal skin using a semiquantitative RT-PCR methodology.
Representative result from ®ve different scar specimens that were 23±56
d old. Lane 1, negative control (without c-DNA); lane 2, scars; lane 3,
normal skin.
Figure 1. SCF immunoreactivity in normal skin versus scar tissue. (a) Normal skin; (b) scar tissue. Immunohistochemistry using the APAAP
technique; scale bar: 100 mm.
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dermis were also increased in fresh scars, however (Table IV). On
mRNA analysis, no differences were noted between the message in
scar and normal tissue (Fig 3, Table I).
Receptor expression on mast cells In contrast to KIT and
NGF-TrkA, cutaneous human mast cells have so far not been
reported to express TRbRI, II, NGF-p75, or GM-CSFR. We
therefore analysed their expression in isolated normal skin mast cells
by FACS analysis or by double staining with combined
¯uorescence/immunohistochemistry in normal and scar tissue.
Normal skin mast cells were found to express both TRb (type I:
16% and 90%, type II: 31% and 83%, n = 2). Furthermore, about
two-thirds of avidin-positive normal skin mast cells exhibited
immunoreactivity for the NGF-p75 and GM-CSFR receptors
(TableV). Interestingly, this reactivity was entirely lost for the
NGFR-p75 and was markedly reduced for the GM-CSFR in scar
tissue (TableV, Fig 6a, b),in agreement with previously reported
observations on mast cells for KIT (Hermes et al, 2000).
DISCUSSION
These ®ndings demonstrate that human scar tissue exhibits an
increased expression of SCF, TGFb1 and its type I and II receptors,
and of the NGF receptors TrkA and p75 at both the protein and
mRNA level. The data are particularly striking for the highly
potent mast cell chemotactic factor TGFb1 and its type I and II
receptors, which have been demonstrated before on human
leukemic mast cells (Olsson et al, 2000), in agreement with these
data. In contrast, the mast cell growth factor NGF and the inhibitor
of human mast cell differentiation GM-CSF were detected at only
minor levels, with no alterations in scar tissue compared with
normal skin. Furthermore, the GM-CSFR was only increased in
the dermis of fresh but not older scars, probably due to the
in¯ammatory in®ltrate that is prominent during early phases of
wound healing (Gearing et al, 1989; Di Marco et al, 1993).
A major goal of this study was the elucidation of the role of
potential mast cell growth modulatory and chemotactic factors
during wound healing. Whereas our data suggest indeed a potential
role of such molecules and their receptors in scar tissue, they might
also only be coincidental. Because expression of the SCF-receptor
is restricted to mast cells and melanocytes in cutaneous tissue, it is
unlikely that SCF plays a role in wound healing other than through
its effects on these cells. Mast cells have, however, been shown in
the past to also induce collagen production via mast cell derived
TGFb (Gordon and Galli, 1994). The previously reported increase
of KIT- and tryptase-positive cells in scars speaks furthermore for
recruitment of mast cell precursors during wound healing due to
the increased availability of SCF, as reported here. There are
abundant potential sources of SCF in scar tissue, based also on the
immunohistochemical staining pattern observed here and reported
previously (Longley et al, 1993; Hamann et al, 1995). Numerous
in¯ammatory stimuli that can activate the secretory response of
SCF-producing cells or alterations of cells in dependence of
ongoing differentiation and maturation might increase SCF
production in scars (Grabbe et al, 1996; Welker et al, 1999).
Finally, alteration of SCF metabolization might play a role. This
could explain the increase of SCF protein in the face of a low
upregulation of SCF message in view of similar ®ndings in
mastocytosis lesions where an increase of soluble SCF by cleavage
of the membrane-bound form of SCF has been postulated (Longley
et al, 1993).
Whereas the role of SCF has so far not been examined in human
scar tissue, NGF has long been established as a factor accelerating
Table I. Densitometric analysis of RT-PCR signal intensity
using primer pairs speci®c for different growth factors and
growth factor receptorsa
Primer speci®c for Scars Normal skin
GAPDH 100 6 30 80 6 25
SCFb 265 6 90** 130 6 70
TGFb 480 6 200* 30 6 10
TRbI 750 6 180* 60 6 30
TRbII 220 6 100* 40 6 20
NGFR-TrkA 950 6 250* 220 6 80
NGFR-p75 350 6 90* 110 6 50
GM-CSFR 120 6 40 110 6 60
aMeans 6 SD of N = 5 (bN = 6), *Signi®cant at p < 0.01; **signi®cant at
p < 0.02 compared with normal skin.
Table II. Immunohistochemical staining (APAAP) for
TGFb1 in normal skin (NS) versus scar tissuea
NS Scars Stat. sign.
(p =)
Epidermis 72.64 6 29.10 141.00 6 68.48 0.0026
Upper dermis 30.35 6 14.80 120.48 6 48.81 0.003
Mid- and lower dermis 4.81 6 6.80 130.71 6 79.66 0.005
aResults are expressed as means 6 SD of positive cells per 6.25 nm width in the
epidermis or as cells per 6.25nm2 in the dermis.
Table III. Immunoreactivity (APAAP) of TGFb-, NGF-,
and GM-CSF-receptors in different cutaneous
compartments of normal skin versus scar tissuea
NS Scars Stat. sign.
(p =)
TGFbRI
epidermis 29.74 6 33.97 114.21 6 54.19 0.000003
upper dermis 7.94 6 7.09 62.35 6 35.45 0.000009
mid- and lower dermis 1.20 6 2.69 65.71 6 35.89 0.0014
TGFbRII
epidermis 90.63 6 33.76 156.47 6 61.74 0.00078
upper dermis 79.65 6 53.26 119.72 6 68.29 ±
mid- and lower dermis 18.5 6 15.58 89.41 6 11.29 0.005
NGFR-TrkA
epidermis 62.17 6 72.13 102.96 6 82.27 ±
upper dermis 5.50 6 6.02 22.04 6 17.79 0.0066
mid- and lower dermis 0.81 6 2.30 18.69 6 18.99 0.0024
NGFR-p75
epidermis 11.76 6 2.36 0.34 6 0.17 0.0001
upper dermis 8.84 6 2.08 8.05 6 2.09 ±
mid- and lower dermis 3.67 6 2.37 10.27 6 1.90 0.0007
GM-CSFR
epidermis 1.33 6 0.44 1.67 6 0.72 ±
upper dermis 2.08 6 0.68 5.08 6 1.62 ±
mid- and lower dermis 0.37 6 0.28 3.52 6 1.77 0.0013
aResults are expressed as means 6 SD of positive cells per 6.25 nm width in the
epidermis and as cells per 6.25nm2 in the dermis. (± = not signi®cant at p > 0.05.)
Table IV. Comparison of immunoreactive dermal cells
towards NGF and GM-CSF receptors in normal skin
sections versus fresh and old scarsa
NGFR-p75 GM-CSFR
Normal dermis (n = 10) 5.20 6 2.38 0.55 6 0.41
Fresh scars (n = 7) 9.38 6 3.82 7.13 6 4.16*
Old scars (n = 13) 9.70 6 2.11 1.88 6 1.41
aCell counts represent means 6 SD of positive cells per 6.25 nm2 in the dermis.
*Note the selective upregulation of GM-CSFR in fresh scars only at p < 0.001,
compared with normal skin.
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wound healing (Hutson et al, 1979). Possible mechanisms might
involve induction of proliferation and differentiation of nerves,
myeloid cells, keratinocytes, melanocytes, and factors produced by
these cells (reviewed in Artuc et al, 1999). Contrary to what might
have been expected against this background, we failed to identify
either a marked expression of NGF in normal skin, or its
upregulation in scars. This may be due to technical reasons, to
failure of or only low level NGF production, or to its rapid
elimination. The ability of cells from different organs to produce
NGF has in fact been shown to be highly variable (Cartwright et al,
1994), and its synthesis in keratinocytes depends on the presence of
stimuli like TNF-a, PDGF, and IL-1 (Di Marco et al, 1991).
Transiently secreted or minor amounts of NGF might nevertheless
exert some effects during wound healing via NGF receptors, which
are signi®cantly increased in scars at the protein and message level
and which can affect epidermal as well as dermal aspects of wound
healing (Matsuda et al, 1988; Di Marco et al, 1993).
Expression of the NGFR-TrkA has been described in keratino-
cytes, monocytes, and cultured mast cells (Pincelli et al, 1994;
Figure 5. GM-CSFR immunoreactivity in normal skin versus scar
tissue. (a) Normal skin; (b) scar tissue. Immunohistochemistry using the
APAAP technique; scale bar: 30 mm.
Figure 6. Double immuno¯uorescent staining for avidin and GM-
CSFR immunoreactivity in scar tissue. (a) Avidin-positive cells; (b)
GM-CSFR-p75 reactivity in the same section. Scale bar: 10 mm.
Figure 4. NGFR-p75 immunoreactivity in normal skin versus scar
tissue. (a) Normal skin; (b) scar tissue. Immunohistochemistry using the
APAAP technique; scale bar: (a) 50 mm, (b) 100 mm. Note reactivity in basal
cells above dermal papillae of normal skin.
TableV. Immunohistochemical staining (APAAP) of
receptors in avidin-positive mast cells in normal skin versus
scar tissuea
NS (N) Scars (N)
NGFR-p75 70% (153) 0% (none found)
GM-CSFR 73% (125) 49% (39)
aTotal numbers of avidin-positive cells, as determined in tissue sections by
immuno¯uorescence microscopy, are shown in parentheses.
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Ehrhard et al, 1993; Nilsson et al, 1997; Tam et al, 1997; Welker
et al, 1998, 2000b), and its upregulation in scars may well be
associated with the increased number and activity of these cells. In
addition to sensory and autonomic nerves, NGFR-p75 expression
has been described only for basal keratinocytes, melanocytes,
Merkel cells, and lymphocytes (reviewed in Artuc et al, 1999). T
lymphocytes have been demonstrated to persist for up to 1 y in scars
(Bothwell, 1997) and may account for the increased NGFR-p75
expression even in old dermal scar tissue (Table IV). The
signi®cant reduction of NGFR-p75 expression in the epidermis
of scars (Table III) may on the other hand be due to denervation,
which has been reported to cause a drop of NGFR-p75 expression
in epithelial tissue (Ribeiro-Da-Silva et al, 1991) and which may
well prevail in scars after sectioning of nerves at the time of surgical
injury. Related or the same mechanisms may also underly the
almost complete reduction of NGFR-p75 on avidin positive mast
cells in scars. Alternative or additional mechanisms other than
denervation may well be operative, however, since the reduction of
growth factors on avidin-positive mast cells was also observed for
GM-CSFR (TableV) and KIT (Hermes et al, 2000).
Other workers have failed so far to demonstrate the NGFR-p75
on human cultured cord blood-derived and leukemic (HMC-1)
mast cells (Nilsson et al, 1997; Tam et al, 1997), although we have
noted mRNA but not protein expression in the HMC-1 subclone
used in our laboratory (Welker et al, 1998). These data that also
show protein expression on avidin-positive skin mast cells suggest
that NGFR-p75 expression on mast cells may depend on the tissue
and/or the state of maturation of the cells. Its complete
downregulation on mature mast cells in scars would indeed speak
for the susceptibility of NGFR-p75 expression to changes in its
microenvironment also on mast cells.
Taken together, these ®ndings suggest that SCF, TGFb1, and
possibly also NGF, via its receptors, may participate in the increase
of KIT+, tryptase+, chymase±, avidin± mast cells in human
cutaneous scar tissue by increasing recruitment, proliferation,
maturation, and survival of these cells. Other mast cell chemotactic
factors like C3a, C5a, and plasminogen activator are likely to exert
this function as well (Hartmann et al, 1997; Sillaber et al, 1997),
particularly during the early phases of wound healing and the
associated acute in¯ammation. The failure to demonstrate GM-
CSF in the scar tissue, as reported here, would favor the
uninhibited early differentiation and maturation of the cells in this
tissue (Du et al, 1997; Welker et al, 1997). On the basis of these
data, it must be assumed that next to TGFb1 and NGF, SCF plays a
role in wound healing, albeit secondarily via the tissue remodeling
effects exerted by increased numbers of mast cells.
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